William William, MD, The University of Texas MD Anderson Cancer Centre, Houston, TX, discusses patient sub-populations that will benefit from antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) and ADC combination strategies for NSCLC. Patients with HER2 mutations or overexpression are indicated to benefit the most from ADCs such as trastuzumab deruxtecan. For tumour-associated calcium signal transducer 2 (TROP-2)-targeting ADCs, no appropriate patient sub-population has been identified as TROP-2 is frequently expressed in NSCLC. Research published about patritumab deruxtecan (an ADC against HER3) has shown efficacy in patients with EGFR mutations in NSCLC. Dr William suggests the most promising combination strategies will use ADCs with immunotherapy and possibly targeted agents in specific sub-populations of patients with actionable genomic alterations, such as MET-ADCs with EGFR inhibitors. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.